Polysaccharide-Based Nanocarriers for Drug Delivery

Teijeiro, C.; McGlone, Adam; Csaba, Nœmi; García-Fuentes, Marcos; Alonso, María José

doi:10.1142/9789814520652_0007

Cited by 9 publications

(8 citation statements)

References 240 publications

(334 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 ). This is in agreement with previous described results using CS-coated NPs of different nature 19 41 , in which the bioadhesive capacity of CS 34 is associated with the increase of NPs cell penetration through an improvement of NP-cell contact 41 42 . To further assess whether these NPs were internalized into the cells, confocal microscopy images were collected at different levels of the Z-axis ( Figures S10–S12 ), detecting the iron self-reflection fluorescence coming from the nanoMOFs at different depths.…”

Section: Resultssupporting

confidence: 93%

“…In lis -SIF medium, uncoated MIL-100(Fe) NPs remained stable up to 24 h, whereas in the case of the CS-coated material a slight aggregation was rapidly observed (240 nm at 4 h). This could be related with the bioadhesive properties of the CS and with the tendency to display neutral surface charge 19 , associated with weaker electrostatic repulsion forces required to stabilize the colloids (ζ-potential values of −51 ± 1 vs . −5 ± 3 mV in MIL-100(Fe) and CS_MIL-100(Fe) NPs, respectively; Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

“…This biocompatible polysaccharide may protect the NPs against enzymatic degradation while provides them with bioadhesion properties, which is suitable for a potential local release of the AI cargo near to the intestinal mucosa. In addition, CS coating could a priori facilitate the transport of AI-containing MOF nanocarriers across mucosal barriers, improving the AI absorption 18 19 . The MIL-100(Fe) material in the form of NPs has been selected due to (i) its easy and biofriendly multigram-synthesis at the nanoscale 20 21 , (ii) its lack of in vivo toxicity 22 , (iii) its exceptional loading of challenging drugs, together with their controlled release under physiological conditions, (iv) its interesting imaging properties 10 and (v) the potential tuning of its biodistribution by the functionalization of its external surface 14 15 .…”

mentioning

confidence: 99%

See 2 more Smart Citations

Chitosan-coated mesoporous MIL-100(Fe) nanoparticles as improved bio-compatible oral nanocarriers

Hidalgo

Giménez‐Marqués

Bellido

et al. 2017

Sci Rep

117

View full text Add to dashboard Cite

Nanometric biocompatible Metal-Organic Frameworks (nanoMOFs) are promising candidates for drug delivery. Up to now, most studies have targeted the intravenous route, related to pain and severe complications; whereas nanoMOFs for oral administration, a commonly used non-invasive and simpler route, remains however unexplored. We propose here the biofriendly preparation of a suitable oral nanocarrier based on the benchmarked biocompatible mesoporous iron(III) trimesate nanoparticles coated with the bioadhesive polysaccharide chitosan (CS). This method does not hamper the textural/structural properties and the sorption/release abilities of the nanoMOFs upon surface engineering. The interaction between the CS and the nanoparticles has been characterized through a combination of high resolution soft X-ray absorption and computing simulation, while the positive impact of the coating on the colloidal and chemical stability under oral simulated conditions is here demonstrated. Finally, the intestinal barrier bypass capability and biocompatibility of CS-coated nanoMOF have been assessed in vitro, leading to an increased intestinal permeability with respect to the non-coated material, maintaining an optimal biocompatibility. In conclusion, the preservation of the interesting physicochemical features of the CS-coated nanoMOF and their adapted colloidal stability and progressive biodegradation, together with their improved intestinal barrier bypass, make these nanoparticles a promising oral nanocarrier.

show abstract

Section: Resultssupporting

confidence: 93%

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Chitosan-coated mesoporous MIL-100(Fe) nanoparticles as improved bio-compatible oral nanocarriers

Hidalgo

Giménez‐Marqués

Bellido

et al. 2017

Sci Rep

117

View full text Add to dashboard Cite

show abstract

“…Although HA-NPs were labeled by 1.5 times more Cy5.5 than HApolymers, the level of fluorescence in the liver was at an even higher state in the HA-NPs group than the HA-polymers group. These results indicate that specific receptors for HA in the liver are molecular weight dependent and show much higher affinity to small-sized particles than large-sized particles [22]. In the current study, in vivo imaging showed that the liver and urinary bladder had much stronger fluorescence than other organs in both groups.…”

Section: Discussionsupporting

confidence: 53%

Long-circulating and target-specific distributions of cyanine 5.5-labeled hyaluronic acid nanoparticles in mouse organs during 28 days after a single administration

Yun¹,

Cai²,

Yon³

et al. 2018

Korean J Vet Res

View full text Add to dashboard Cite

Although hyaluronic acid (HA) has been developed as a nanoparticle (NP; 320-400 nm) for a drug delivery system, the tissue targeting efficacy and the pharmacokinetics of HA-NPs are not yet fully understood. After a dose of 5 mg/kg of cyanine 5.5-labeled HA-NPs or HA-polymers was intravenously administrated into mice, the fluorescence was measured from 0.5 h to 28 days. The HA-NPs fluorescence was generally stronger than that of HA-polymers, which was maintained at a high level over 7 days in vivo, after which it gradually decreased. Upon ex vivo imaging, liver, spleen, kidney, lung, testis and sublingual gland fluorescences were much higher than that of other organs. The fluorescence of HA-NPs in the liver, spleen and kidney was highest at 30 min, where it was generally maintained until 4 h, while it drastically decreased at 1 day. However, the fluorescence in the liver and spleen increased sharply at 7 days relative to 3 days, then decreased drastically at 14 days. Conversely, the fluorescence of HA-polymers in the lymph node was higher than that of HA-NPs. The results presented herein may have important clinical implications regarding the safety of as self-assembled HA-NPs, which can be widely used in biomedical applications.

show abstract

“…However, up to now, the therapeutic use of mAbs is restricted to extracellular or membrane-bound proteins (20), due to their inefficient intracellular delivery by endocytosis (21). To overcome this obstacle, we have used here biocompatible hyaluronic acid (HA) nanocapsules (NC), capable of releasing small cytostatic drugs and genetic material into cancer cells (22,23), as vehicles for intracellular delivery of an anti-GSDMB antibody in HER2/GSDMB þ cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness

Molina-Crespo

Cadete

Sarrió

et al. 2019

Clinical Cancer Research

123

View full text Add to dashboard Cite

Purpose: Gasdermin B (GSDMB) overexpression/amplification occurs in about 60% of HER2 breast cancers, where it promotes cell migration, resistance to anti-HER2 therapies, and poor clinical outcome. Thus, we tackle GSDMB cytoplasmic overexpression as a new therapeutic target in HER2 breast cancers. Experimental Design: We have developed a new targeted nanomedicine based on hyaluronic acid-biocompatible nanocapsules, which allow the intracellular delivery of a specific anti-GSDMB antibody into HER2 breast cancer cells both in vitro and in vivo. Results: Using different models of HER2 breast cancer cells, we show that anti-GSDMB antibody loaded to nanocapsules has significant and specific effects on GSDMBoverexpressing cancer cells' behavior in ways such as (i) lowering the in vitro cell migration induced by GSDMB; (ii) enhancing the sensitivity to trastuzumab; (iii) reducing tumor growth by increasing apoptotic rate in orthotopic breast cancer xenografts; and (iv) diminishing lung metastasis in MDA-MB-231-HER2 cells in vivo. Moreover, at a mechanistic level, we have shown that AbGB increases GSDMB binding to sulfatides and consequently decreases migratory cell behavior and may upregulate the potential intrinsic procell death activity of GSDMB. Conclusions: Our findings portray the first evidence of the effectiveness and specificity of an antibody-based nanomedicine that targets an intracellular oncoprotein. We have proved that intracellular-delivered anti-GSDMB reduces diverse protumor GSDMB functions (migration, metastasis, and resistance to therapy) in an efficient and specific way, thus providing a new targeted therapeutic strategy in aggressive HER2 cancers with poor prognosis.

show abstract

Polysaccharide-Based Nanocarriers for Drug Delivery

Cited by 9 publications

References 240 publications

Chitosan-coated mesoporous MIL-100(Fe) nanoparticles as improved bio-compatible oral nanocarriers

Chitosan-coated mesoporous MIL-100(Fe) nanoparticles as improved bio-compatible oral nanocarriers

Long-circulating and target-specific distributions of cyanine 5.5-labeled hyaluronic acid nanoparticles in mouse organs during 28 days after a single administration

Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness

Contact Info

Product

Resources

About